Latest news with #Bio-Techne
Yahoo
3 days ago
- Business
- Yahoo
Bio-Techne Corporation (TECH): A Bull Case Theory
We came across a bullish thesis on Bio-Techne Corporation (TECH) on scuttleblurb's Substack. In this article, we will summarize the bulls' thesis on TECH. Bio-Techne Corporation (TECH)'s share was trading at $47.93 as of 28th May. TECH's trailing and forward P/E were 57.75 and 22.03 respectively according to Yahoo Finance. A close-up of a biotechnology machine working on an oncology therapy. Bio-Techne has built a diverse and complex business centered on its strong legacy in recombinant proteins, expanding downstream into antibodies, assays, and instrument platforms, while also moving into cell and gene therapy (CGT) solutions. Its revenue is split roughly between Protein Sciences and Diagnostics, which are closely linked—diagnostics identify disease biomarkers that then become therapeutic targets developed using Bio-Techne's proteins and antibodies. Despite about 20 acquisitions over the past decade, its core legacy products still contribute 56% of total revenue, with the remainder coming from faster-growing, less penetrated markets. Around half of Bio-Techne's revenue comes from commercial R&D, now dominated by smaller, venture-funded biotechs rather than big pharma, making this segment more cyclical. Academia accounts for another 20%, a price-sensitive group vulnerable to budget swings. The company is gaining ground in GMP protein production for clinical and commercial use, a highly regulated and lucrative niche, though it trails established leaders like Miltenyi and Cellgenix. Bio-Techne has also expanded into proteomics and spatial biology through acquisitions. While the company once forecasted nearly $2 billion in revenue by 2026, growth slowed due to several factors: COVID-related demand spikes followed by inventory destocking, a 20-30% revenue decline in China, fading COVID testing tailwinds, and cautious FDA oversight of CGTs that hurt growth expectations. Despite these setbacks causing a nearly 50% stock price decline, recent signs point to recovery with organic growth rebounding to 9% and instrument sales improving. Bio-Techne's broad strategy reflects its efforts to protect core franchises while expanding into new growth areas, including becoming an instrument provider to capture more downstream value. Bio-Techne Corporation (TECH) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held TECH at the end of the first quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of TECH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TECH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
06-05-2025
- Business
- Yahoo
Earnings To Watch: Bio-Techne (TECH) Reports Q1 Results Tomorrow
Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results tomorrow before market hours. Here's what you need to know. Bio-Techne beat analysts' revenue expectations by 4.2% last quarter, reporting revenues of $297 million, up 9% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts' organic revenue estimates and a decent beat of analysts' EPS estimates. Is Bio-Techne a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Bio-Techne's revenue to grow 4.6% year on year to $317.4 million, improving from the 3.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.51 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bio-Techne has missed Wall Street's revenue estimates five times over the last two years. Looking at Bio-Techne's peers in the research tools & consumables segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Mettler-Toledo's revenues decreased 4.6% year on year, beating analysts' expectations by 1%, and Danaher reported flat revenue, topping estimates by 2.7%. Mettler-Toledo traded up 4.3% following the results while Danaher was also up 6.2%. Read our full analysis of Mettler-Toledo's results here and Danaher's results here. There has been positive sentiment among investors in the research tools & consumables segment, with share prices up 4.4% on average over the last month. Bio-Techne is down 4.8% during the same time and is heading into earnings with an average analyst price target of $79.70 (compared to the current share price of $49.80). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Yahoo
24-04-2025
- Business
- Yahoo
Bio-Techne Corporation (TECH) Slid Due to NIH's Funding Concerns
Aristotle Atlantic Partners, LLC, an investment advisor, released its 'Large Cap Growth Strategy' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market experienced a modest decline in Q1 2025, with the S&P 500 Index falling 4.27%, while bonds showed stability with the Bloomberg U.S. Aggregate Bond Index rising 2.78%. In the first quarter, Aristotle Atlantic's Large Cap Growth Strategy delivered -9.55% gross of fees (-9.68% net of fees), outperforming the Russell 1000 Growth Index's -9.97% return. Security selection led the portfolio to outperform in the quarter. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Aristotle Atlantic Large Cap Growth Strategy highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $7.93 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -16.33%, and its shares lost 19.95% of their value over the last 52 weeks. On April 23, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $50.16 per share. Aristotle Atlantic Large Cap Growth Strategy stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2025 investor letter: "Bio-Techne Corporation (NASDAQ:TECH) detracted from performance in the first quarter on fears around National Institutes of Health (NIH) funding concerns. The Trump administration announced caps on administrative costs for NIH-funded research projects, and this has resulted in fears of a slowdown in the academic and government segment. Bio-Techne has recently stated that its view is, worst case, a possible 50 basis point headwind to growth. Bio-Techne has shown positive momentum following a strong fiscal second quarter earnings report that included organic revenue growth of 9%." A cutting-edge laboratory with technicians in white coats studying a POC device. Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the fourth quarter compared to 25 in the third quarter. In the second quarter of fiscal 2025, the company generated $297 million in revenues, up 9% year-over-year on both reported and organic basis. While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Bio-Techne Corporation (NASDAQ:TECH) and shared the list of best gene therapy stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
18-04-2025
- Business
- Yahoo
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let's take a look at how Illumina (NASDAQ:ILMN) and the rest of the life sciences tools & services stocks fared in Q4. The life sciences tools and services sector supports the research, development, and commercialization of biotechnology and pharmaceutical products. These companies offer a broad range of tools, from lab consumables and testing equipment to data analytics platforms and clinical trial support. There is recurring revenue potential from long-term contracts, high margins from specialized products, and the growing demand for precision medicine and data-driven insights. However, challenges include dependence on research and development budgets from large pharmaceutical companies and the boom and bust nature of smaller biotech companies. Looking forward, the life sciences tools and services sector is expected to benefit from strong tailwinds, including advancements in genomics and the rising focus on personalized medicine. Ongoing adoption of artificial intelligence in research and drug discovery, along with the growing need for regulatory compliance and data analytics, should provide longer-term demand support. However, headwinds such as the uncertainty around healthcare and research funding as well as pricing pressures from cost-conscious customers may feed into uncertainty in the sector. The 21 life sciences tools & services stocks we track reported a mixed Q4. As a group, revenues beat analysts' consensus estimates by 1.1% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 29.1% since the latest earnings results. Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ:ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions. Illumina reported revenues of $1.10 billion, flat year on year. This print exceeded analysts' expectations by 2.1%. Overall, it was a strong quarter for the company with a solid beat of analysts' full-year EPS guidance estimates. "The Illumina team delivered fourth quarter revenue that exceeded our expectations, and we made significant progress in 2024 toward our goals to drive customer-centric innovation, margin expansion, and EPS growth," said Jacob Thaysen, Chief Executive Officer. The stock is down 41% since reporting and currently trades at $72.40. Is now the time to buy Illumina? Access our full analysis of the earnings results here, it's free. With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Bio-Techne reported revenues of $297 million, up 9% year on year, outperforming analysts' expectations by 4.2%. The business had an exceptional quarter with a solid beat of analysts' organic revenue estimates and a decent beat of analysts' EPS estimates. Bio-Techne delivered the biggest analyst estimates beat among its peers. The stock is down 31.8% since reporting. It currently trades at $49.52. Is now the time to buy Bio-Techne? Access our full analysis of the earnings results here, it's free. Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. PacBio reported revenues of $39.22 million, down 32.8% year on year, falling short of analysts' expectations by 1.8%. It was a disappointing quarter as it posted a miss of analysts' EPS estimates. PacBio delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 20.4% since the results and currently trades at $1.17. Read our full analysis of PacBio's results here. Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized equipment, software, and services for biotechnology, life sciences, and diagnostics. Danaher reported revenues of $6.54 billion, up 2.1% year on year. This number surpassed analysts' expectations by 1.6%. Overall, it was a strong quarter as it also put up an impressive beat of analysts' organic revenue estimates. The stock is down 24.2% since reporting and currently trades at $187.84. Read our full, actionable report on Danaher here, it's free. With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Bruker reported revenues of $979.6 million, up 14.6% year on year. This print beat analysts' expectations by 1.4%. Zooming out, it was a mixed quarter as it also logged a solid beat of analysts' organic revenue estimates. The stock is down 29.8% since reporting and currently trades at $36.28. Read our full, actionable report on Bruker here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Yahoo
18-04-2025
- Business
- Yahoo
Reflecting On Research Tools & Consumables Stocks' Q4 Earnings: Agilent (NYSE:A)
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let's have a look at Agilent (NYSE:A) and its peers. The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q4. As a group, revenues beat analysts' consensus estimates by 1.3% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 26.1% since the latest earnings results. Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies (NYSE:A) provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets. Agilent reported revenues of $1.68 billion, up 1.4% year on year. This print exceeded analysts' expectations by 0.6%. Despite the top-line beat, it was still a slower quarter for the company with some shareholders anticipating a better outcome. The stock is down 23% since reporting and currently trades at $103.49. Read our full report on Agilent here, it's free. With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Bio-Techne reported revenues of $297 million, up 9% year on year, outperforming analysts' expectations by 4.2%. The business had an exceptional quarter with a solid beat of analysts' organic revenue estimates and a decent beat of analysts' EPS estimates. Bio-Techne scored the biggest analyst estimates beat among its peers. The stock is down 31.8% since reporting. It currently trades at $49.52. Is now the time to buy Bio-Techne? Access our full analysis of the earnings results here, it's free. With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries. Avantor reported revenues of $1.69 billion, down 2.1% year on year, falling short of analysts' expectations by 1.6%. It was a softer quarter as it posted a miss of analysts' organic revenue estimates. Avantor delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 28.9% since the results and currently trades at $15.41. Read our full analysis of Avantor's results here. Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters (NYSE:WAT) develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing. Waters Corporation reported revenues of $872.7 million, up 6.5% year on year. This result surpassed analysts' expectations by 1.9%. Zooming out, it was a decent quarter as it also recorded a solid beat of analysts' organic revenue estimates. The stock is down 20.8% since reporting and currently trades at $321.01. Read our full, actionable report on Waters Corporation here, it's free. With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Bruker reported revenues of $979.6 million, up 14.6% year on year. This print beat analysts' expectations by 1.4%. Taking a step back, it was a mixed quarter as it also logged an impressive beat of analysts' organic revenue estimates but full-year revenue guidance missing analysts' expectations. Bruker scored the fastest revenue growth but had the weakest full-year guidance update among its peers. The stock is down 29.8% since reporting and currently trades at $36.28. Read our full, actionable report on Bruker here, it's free. Thanks to the Fed's series of rate hikes in 2022 and 2023, inflation has cooled significantly from its post-pandemic highs, drawing closer to the 2% goal. This disinflation has occurred without severely impacting economic growth, suggesting the success of a soft landing. The stock market thrived in 2024, spurred by recent rate cuts (0.5% in September and 0.25% in November), and a notable surge followed Donald Trump's presidential election win in November, propelling indices to historic highs. Nonetheless, the outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. The path forward holds both optimism and caution as new policies take shape. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
